The changing burden of gout in adults aged 70 and above based on the global burden of disease 2019

Frontiers in Public Health, Год журнала: 2025, Номер 13

Опубликована: Фев. 6, 2025

Gout is a significant global health issue, particularly among adults aged 70 and above. Understanding its epidemiological evolution associated factors crucial for guiding interventions improving management. This study analyzed data from the Global Burden of Disease to assess prevalence trends gout above 1990 2019. We evaluated temporal regional disparities by calculating estimated annual percentage change (EAPCs). Globally, number older individuals affected increased 5,316,210 cases in 15,666,063 It noteworthy that burden continued rise 2019, with an EAPC 1.17 (95% CI: 1.02 1.32). In rates 70-74, 75-79, 80-84, 85 were 3,121.31 per 100,000, 3,437.17 3,592.38 3,726.91 respectively. The regions highest 2019 Australasia, High-income North America, Southern Latin 8,500.73, 8,351.33, 4,666.87 At national level, some developed countries such as New Zealand, United States Australia had rates, reaching 8,893.74, 8,508.06, 8,427.94 higher levels Socio-Demographic Index tended have relatively adults, varied across different age groups. underscores persistent emphasizing need targeted address this issue improve public outcomes demographic.

Язык: Английский

---

Lowering the risk of hyperuricemia and gout is associated with ideal cardiovascular health

Journal of Health Population and Nutrition, Год журнала: 2024, Номер 43(1)

Опубликована: Окт. 24, 2024

Язык: Английский

---

Dual benefits of sodium-glucose cotransporter 2 inhibitors in metabolic diseases: Diabetes control and gout management

World Journal of Clinical Cases, Год журнала: 2025, Номер 13(14)

Опубликована: Янв. 14, 2025

The study by Lin et al delves into the clinical impact of dapagliflozin, a representative sodium-glucose cotransporter 2 (SGLT2) inhibitor, on chronic heart failure complicated hyperuricemia. This investigation highlights dapagliflozin’s efficacy in lowering serum uric acid levels, enhancing cardiac function, and reducing cardiovascular events. work not only provides comprehensive analysis sustained benefits these patients but also introduces novel insights for managing exacerbated elevated acid. Furthermore, this review examines potential role SGLT2 inhibitor context gout, evaluating its mechanisms application prospects management hyperuricemia, thereby further enriching medical community’s understanding inhibitor.

Язык: Английский

---

Therapeutic potential and pharmacological mechanisms of Traditional Chinese Medicine in gout treatment

Acta Pharmacologica Sinica, Год журнала: 2025, Номер unknown

Опубликована: Янв. 17, 2025

Язык: Английский

---

Gout

Annals of Internal Medicine, Год журнала: 2025, Номер unknown

Опубликована: Март 10, 2025

Gout is characterized by deposition of monosodium urate (MSU) crystals in or around joints, tendons, bursae, and other tissues, resulting painful recurrent flares tissue damage. the most common form inflammatory arthritis, with a prevalence 5.1% United States, affecting 12.1 million adults. When levels exceed limit solubility (6.8 mg/dL [400 μmol/L]), MSU may grow. are result responses to crystals. The primary method prevent reduce gout flares, tophi, chronic joint damage below saturation threshold. pathophysiology well understood, inexpensive effective therapies available. However, outcomes for patients remain poorly optimized.

Язык: Английский

---

SGLT2 Inhibitors and Uric Acid Homeostasis

Gout Urate and Crystal Deposition Disease, Год журнала: 2024, Номер 2(2), С. 157 - 172

Опубликована: Май 31, 2024

A relationship between metabolic disorders and hyperuricemia is well established. The nature of the relationship—risk factor, causal agent, or byproduct—remains unclear. Recent studies sodium–glucose transporter 2 inhibitors (SGLT2i’s) have established that this pharmacological intervention beneficial to patients with hyperglycemia type diabetes mellitus (T2D) also against common cardio renal comorbidities associated diabetes. Hyperuricemia, high plasma uric acid levels, one mitigated SGLT2i treatment, raising potential for using SGLT2i’s as part treatment gout hyperuricemia. However, mechanisms underlying lower urate levels increased uricosuria produced remains poorly understood. Here, we review physiology glucose transport, consequences hyperglycosuria diabetes, benefits use, discuss several may be responsible favorable uricosuric effect observed in those treated SGLT2i’s.

Язык: Английский

---

Translational research on cognitive impairment in chronic kidney disease

Nephrology Dialysis Transplantation, Год журнала: 2024, Номер unknown

Опубликована: Окт. 14, 2024

ABSTRACT Cognitive decline is common in patients with acute or chronic kidney disease. Several areas of brain function can be affected, including short- and long-term memory, attention inhibitory control, sleep, mood, eating control motor function. disease shares risk factors cognitive dysfunction people without disease, such as diabetes, high blood pressure, sedentary lifestyle unhealthy diet. However, additional kidney-specific may contribute, uremic toxins, electrolyte imbalances, inflammation, acid–base disorders endocrine dysregulation. Traditional interact to cause damage the blood–brain barrier, induce vascular neurotoxicity neuroinflammation. Here, we discuss recent insights into pathomechanisms from animal models novel avenues for prevention therapy. We focus on a several that influence cognition: barrier disruption, role skeletal muscle, physical activity factor irisin, emerging therapeutic sodium-glucose cotransporter 2 (SGLT2) inhibitors glucagon-like peptide 1 (GLP-1) receptor agonists. Taken together, these studies demonstrate importance providing mechanistic understanding this complex condition their potential explain mechanisms therapies.

Язык: Английский

---

Gout and Hyperuricemia: A Narrative Review of Their Comorbidities and Clinical Implications

Journal of Clinical Medicine, Год журнала: 2024, Номер 13(24), С. 7616 - 7616

Опубликована: Дек. 13, 2024

Gout is the most common form of inflammatory arthritis, caused by deposition monosodium urate crystals in joints due to elevated serum uric acid levels. Its prevalence and associated healthcare burden have been rising recent decades, a trend expected continue. It crucial recognize that gout hyperuricemia are not merely causes painful joint flares, but systemic metabolic disorders linked broad spectrum comorbidities such as cardiovascular diseases, chronic kidney disease, diabetes, insulin resistance, steatotic liver osteoarthritis, respiratory eye diseases. Numerous risk factors for identified, with research uncovering further associations other conditions. To optimize patient outcomes, must be addressed through holistic approach accounts these while providing comprehensive management related affecting various organ systems. This review summarizes current knowledge on factors, comorbidities, clinical implications hyperuricemia. Future should focus improving outcomes tailoring treatments individually addressing underlying multimodal treatment.

Язык: Английский

---

SGLT-2 inhibitors: Diabetes and CKD and CHF (and gout?), oh my!

Cleveland Clinic Journal of Medicine, Год журнала: 2024, Номер 91(7), С. 392 - 393

Опубликована: Июль 1, 2024

Hyperglycemia is the hallmark characteristic of diabetes mellitus.Blood glucose and hemoglobin A1c are guideline-driven markers useful for diagnosis monitoring treatment.But blood but 1 part this systemic metabolic disease that also has infl ammatory components."Successful" aggressive control sugar had limited success in preventing onset progression cardiovascular renal damage.Many our patients still struggle with ischemic heart disease, failure, peripheral arterial kidney disease.There have been several new US Food Drug Administration (FDA)-approved medications to treat type 2 diabetes, some which use unique physiologically targeted mechanisms lower glucose.The FDA drug approval process mandated increased attention be given studying effects potential drugs on components mellitus, not just their hypoglycemic activity.The initial focus was excluding unanticipated detrimental effects.Studies were large, prospectively planned collection detailed data, events carefully adjudicated.As a result, it demonstrated newer capable lowering by novel only cardiac safe, somewhat surprisingly able reduce (and renal) morbidities.Jaswaney et al issue Journal discuss sodium-glucose cotransporter (SGLT-2) inhibitors failure chronic including those without diabetes.These effective adjuncts levels.Designed work inducing glucosuria anticipated reductions circulating insulin levels there reason think they could might exacerbated hyperinsulinemia.It welcome surprise bit confusing) many us practicing primarily arena clinical trials multiple class effi cacy decreasing admissions (for reduced as well maintained ejection fraction), all-cause mortality, disease.And, these benefi ts found diabetes.Perhaps surprisingly, incidences myocardial infarction stroke apparently signifi cantly reduced, raising further questions about mechanism action.But seems quite unlikely from induced resultant relative hypoglycemia.So how does gout enter into discussion?Gout prototypic autoinfl may occur long-standing hyperuricemia (generally defi ned level above urate's estimated vivo saturation point 6.8 mg/dL), can result deposition monosodium urate around joints sometimes organs, kidney.The physiologic basis most ineffi cient intestinal excretion, latter being due excess reabsorption uric acid proximal tubules.Although dramatic

Язык: Английский

---

Managing Gout in Patients with Metabolic Syndrome

Drugs & Aging, Год журнала: 2024, Номер 41(8), С. 653 - 663

Опубликована: Июль 27, 2024

Язык: Английский

---